Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/219634
Eficacia, seguridad y tolerabilidad de cariprazina en el trastorno depresivo mayor: una revisión sistemática y aspectos prácticos
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
[spa]
Cariprazina es un antipsicótico de nueva generación cuyo mecanismo de acción se basa en el agonismo parcial de los receptores de la dopamina D2 y D3, además de los receptores de serotonina 5HT1A. El uso de cariprazina ha sido aprobado por la Agencia Española del Medicamento para el tratamiento de la esquizofrenia. Sin embargo, la literatura científica ha demostrado también su eficacia en episodios maníacos, mixtos y depresivos del trastorno bipolar, indicaciones aprobadas en Estados Unidos y otros países. Asimismo, en la actualidad, se dispone de evidencia acerca de la eficacia clínica, la seguridad y la tolerabilidad de cariprazina como tratamiento adyuvante en el trastorno depresivo mayor, indicación recientemente aprobada por la Food and Drug Administration (FDA). Aunque 3 ensayos clínicos han mostrado resultados negativos, otros 2 han observado una reducción significativa de los síntomas depresivos y ansiosos, lo cual ha sido confirmado además en un ensayo abierto de larga duración. A pesar de presentar un perfil favorable de efectos adversos en comparación con otros antipsicóticos, cariprazina se ha asociado con acatisia e inquietud. Con base en la evidencia actual, el uso de cariprazina como coadyuvante en el tratamiento antidepresivo puede ser beneficioso en pacientes con trastorno depresivo mayor, especialmente cuando se ha producido una respuesta insuficiente a antidepresivos tradicionales. Futuros estudios permitirán elucidar su eventual eficacia en monoterapia y su papel en la prevención de recurrencias depresivas.
[eng] Cariprazine is a new generation antipsychotic whose mechanism of action is based on partial agonism of dopamine D2 and D3 receptors, in addition to serotonin 5HT1A receptors. Its use has been approved by the Spanish Agency of Medicines and Medical Devices for the treatment of schizophrenia. However, the available literature has demonstrated its efficacy in the treatment of manic, mixed, and depressive episodes of bipolar disorder, all them approved indication in the United Sattes and several other countries. Likewise, there is currently evidence regarding the clinical efficacy, safety, and tolerability of cariprazine as an adjunctive treatment in major depressive disorder, which has granted this compound the approval by the Food and Drug Administration (FDA). While three clinical trials have shown negative results, two others have observed a significant reduction in depressive and anxiety symptoms, which has also been confirmed in a long-term open-label trial. Despite presenting a favorable adverse effect profile compared to other antipsychotics, cariprazine has been associated with akathisia and restlessness. Based on current evidence, the use of cariprazine as an adjunctive treatment to antidepressants may be beneficial in major depressive disorder. Future studies may address its efficacy in monotherapy, and its role in the prevention of depressive recurrences.
[eng] Cariprazine is a new generation antipsychotic whose mechanism of action is based on partial agonism of dopamine D2 and D3 receptors, in addition to serotonin 5HT1A receptors. Its use has been approved by the Spanish Agency of Medicines and Medical Devices for the treatment of schizophrenia. However, the available literature has demonstrated its efficacy in the treatment of manic, mixed, and depressive episodes of bipolar disorder, all them approved indication in the United Sattes and several other countries. Likewise, there is currently evidence regarding the clinical efficacy, safety, and tolerability of cariprazine as an adjunctive treatment in major depressive disorder, which has granted this compound the approval by the Food and Drug Administration (FDA). While three clinical trials have shown negative results, two others have observed a significant reduction in depressive and anxiety symptoms, which has also been confirmed in a long-term open-label trial. Despite presenting a favorable adverse effect profile compared to other antipsychotics, cariprazine has been associated with akathisia and restlessness. Based on current evidence, the use of cariprazine as an adjunctive treatment to antidepressants may be beneficial in major depressive disorder. Future studies may address its efficacy in monotherapy, and its role in the prevention of depressive recurrences.
Matèries (anglès)
Citació
Citació
GIMÉNEZ PALOMO, Anna, ILZARBE, Lidia, VIETA I PASCUAL, Eduard. Eficacia, seguridad y tolerabilidad de cariprazina en el trastorno depresivo mayor: una revisión sistemática y aspectos prácticos. _Psiquiatría Biológica_. 2024. Vol. 31, núm. 4. [consulta: 27 de gener de 2026]. ISSN: 1134-5934. [Disponible a: https://hdl.handle.net/2445/219634]